Alpha Teknova, Inc. (TKNO) stock
TKNONasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 12/30150% above fair value
$8.29−0.32 (-3.77%)
Close on Nov 12, 2026Market cap $445.34MP/E –Yield –
Alpha Teknova ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Alpha Teknova's ebitda for the twelve months ending Sep 30, 2026 was -$8.66M. For fiscal 2025 it was -$10.63M. The highest annual figure on record is $6.71M in fiscal 2020.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$10.63M | – |
| FY2024 | Dec 31, 2024 | -$19.57M | – |
| FY2023 | Dec 31, 2023 | -$29.90M | – |
| FY2022 | Dec 31, 2022 | -$46.49M | – |
| FY2021 | Dec 31, 2021 | -$9.13M | -236.1% |
| FY2020 | Dec 31, 2020 | $6.71M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$1.62M | – |
| Q2 FY2026 | Jun 30, 2026 | -$1.30M | – |
| Q1 FY2026 | Mar 31, 2026 | -$2.72M | – |
| Q4 FY2025 | Dec 31, 2025 | -$3.03M | – |
| Q3 FY2025 | Sep 30, 2025 | -$2.43M | – |
| Q2 FY2025 | Jun 30, 2025 | -$1.80M | – |
| Q1 FY2025 | Mar 31, 2025 | -$3.38M | – |
| Q4 FY2024 | Dec 31, 2024 | -$3.98M | – |
| Q3 FY2024 | Sep 30, 2024 | -$5.76M | – |
| Q2 FY2024 | Jun 30, 2024 | -$3.47M | – |
| Q1 FY2024 | Mar 31, 2024 | -$6.35M | – |
| Q4 FY2023 | Dec 31, 2023 | -$9.25M | – |
| Q3 FY2023 | Sep 30, 2023 | -$7.14M | – |
| Q2 FY2023 | Jun 30, 2023 | -$5.70M | – |
| Q1 FY2023 | Mar 31, 2023 | -$7.82M | – |
| Q4 FY2022 | Dec 31, 2022 | -$13.34M | – |
| Q3 FY2022 | Sep 30, 2022 | -$22.23M | – |
| Q2 FY2022 | Jun 30, 2022 | -$5.83M | – |
| Q1 FY2022 | Mar 31, 2022 | -$5.09M | – |
| Q4 FY2021 | Dec 31, 2021 | -$3.98M | -391.7% |
| Q3 FY2021 | Sep 30, 2021 | -$3.14M | -216.6% |
| Q2 FY2021 | Jun 30, 2021 | -$1.83M | – |
| Q1 FY2021 | Mar 31, 2021 | -$176.00K | – |
| Q4 FY2020 | Dec 31, 2020 | $1.37M | – |
| Q3 FY2020 | Sep 30, 2020 | $2.69M | – |
See a number that looks wrong?